 Ardelyx NASDAQ: ARDX stock is taking off on Thursday after an advisory committee to the U.S. Food and Drug Administration FDA voted in favor of its kidney disease drug. This saw the FDAs Cardiovascular and Renal Drugs Advisory Committee vote that the benefits of XPHOZAH outweigh the risks. 